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1. INTRODUCTION {#cam42237-sec-0005}
===============

Bladder carcinoma represents the first and second most common urological malignancy in China and USA, respectively.[1](#cam42237-bib-0001){ref-type="ref"}, [2](#cam42237-bib-0002){ref-type="ref"} Radical cystectomy is the main treatment modality for muscle‐invasive and high‐risk nonmuscle‐invasive urothelial carcinoma of the bladder.[3](#cam42237-bib-0003){ref-type="ref"} Although open surgery remains the most commonly adopted surgical approach, robot‐assisted radical cystectomy (RARC) has evolved over the last few years to become an acceptable option for patients with bladder cancer.

With advances in da Vinci robot systems and surgical skills, three‐year overall survival (OS) rates after RARC have reached 61%‐80%.[4](#cam42237-bib-0004){ref-type="ref"} Noteworthy, some bladder cancer patients still die within the first year from RARC. The preoperative identification of these patients has a strong clinical value, since these patients can be selected for neoadjuvant chemotherapy rather than upfront surgery. However, it is difficult to identify patients who are at high risk of early mortality due to the poor prognostic value of the traditional TNM staging system.

Previous researches have identified various predictors of early mortality among patients receiving radical cystectomy, but few of them included only preoperative factors.[5](#cam42237-bib-0005){ref-type="ref"}, [6](#cam42237-bib-0006){ref-type="ref"}, [7](#cam42237-bib-0007){ref-type="ref"} The objective of this study was to explore preoperative predictors associated with higher risk of early death (within 1 year after RARC) for bladder cancer patients.

2. METHODS {#cam42237-sec-0006}
==========

We retrospectively reviewed 186 patients with bladder cancer who underwent RARC between October 2014 and May 2017 in our institution. No bladder cancer patients received neoadjuvant chemotherapy before RARC. The primary objective was the identification of preoperative predictors of early death, which were defined as death within 1 year of RARC.[8](#cam42237-bib-0008){ref-type="ref"} The following variables were studied: patient age, gender, American Societyof Anesthesiologists (ASA) score, body mass index (BMI), no. of tumors, preoperative clinical stage, and hydronephrosis. Preoperative laboratory evaluation should include complete blood count, fibrinogen, and liver function testing.

The endpoint of the study was OS, which was calculated from the day of surgery to the time of any‐cause mortality, or was censored at the date of recent follow‐up.[9](#cam42237-bib-0009){ref-type="ref"}, [10](#cam42237-bib-0010){ref-type="ref"} PNI was calculated as albumin level (g/L) + 5 × lymphocyte count (10^9^/L),[10](#cam42237-bib-0010){ref-type="ref"} NLR as neutrophil/lymphocyte count, PLR as platelet/lymphocyte ratio, LMR as lymphocyte/monocyte count, and AGR as albumin/(total protein‐albumin).[10](#cam42237-bib-0010){ref-type="ref"} Receiver operating characteristic (ROC) curve analysis was used to compare the prognostic ability of each indicator for each OS event according to the area under the ROC curve (AUC) and to determine the best cutoff points.[10](#cam42237-bib-0010){ref-type="ref"} Patients were classified into two categories according to the cutoff values.

Cox univariate analysis was used to identify prognostic factors for predicting 1‐year OS, estimating hazard ratios (HRs), and 95% confidence intervals (CIs). Factors significant on univariate analysis were included in Cox proportional‐hazards multivariate models.[10](#cam42237-bib-0010){ref-type="ref"} Analyses were performed using SPSS version 20.0 (SPSS, Chicago, IL). All tests were two‐sided and a *P* \< 0.05 was considered statistically significant.

3. RESULTS {#cam42237-sec-0007}
==========

A total of 186 patients were included in this study. The clinicopathological characteristics of all patients are shown in Table [1](#cam42237-tbl-0001){ref-type="table"}. Median patient age was 65 years (IQR 32 to 86), 66.1% of the patients were older than 60 years of age, 84.4% of the patients were men, 14.0% had ASA score ≥3, 47.3% had multiple tumors and 26.3% had hydronephrosis. The tumor stage of all patients was ≤T1 for 39 (21.0%), T2 for 125 (67.2%), T3 or higher for 22 (11.8%). Median fibrinogen was 3.13 (IQR 1.22‐6.26), NLR: 2.62 (IQR 0.63‐34.5), PLR: 129.13 (IQR 34.55‐830.00), LMR: 3.33 (IQR 0.34‐8.28), AGR: 1.58 (IQR 0.73‐2.97), PNI: 47.0 (IQR 27.2‐63.1).

###### 

Patient demographics and clinical characteristics of bladder cancer patients who received RARC

  Variable                     All patients, N = 186
  ---------------------------- -----------------------
  Age, years, median (IQR)     65 (32‐86)
  Gender, n (%)                 
  Male                         157 (84.4)
  Female                       29 (15.6)
  BMI, kg/m^2^, median (IQR)   24.7 (16‐45)
  ASA score ≥3, n (%)          26 (14.0)
  No. of tumors, n (%)          
  Solitary                     98 (52.7)
  Multiple                     88 (47.3)
  Hydronephrosis, n (%)         
  Absent                       137 (73.7)
  Unilateral                   34 (18.3)
  Bilateral                    15 (8.1)
  Clinical stage, n (%)        
  ≤T1                          39 (21.0)
  T2                           125 (67.2)
  ≥T3                          22 (11.8)
  Pathological type, n (%)     
  UC                           176 (94.6)
  NUC                          10 (5.4)
  Pathological grade, n (%)     
  PUNLMP                       8 (4.3)
  LGPUC                        62 (33.3)
  HGPUC                        90 (48.4)
  Fibrinogen, median (IQR)     3.13 (1.22‐6.26)
  NLR, median (IQR)            2.62 (0.63‐34.5)
  PLR, median (IQR)            129.13 (34.55‐830.00)
  LMR, median (IQR)            3.33 (0.34‐8.28)
  AGR, median (IQR)            1.58 (0.73‐2.97)
  PNI, median (IQR)            47.0 (27.2‐63.1)

Abbreviations: AGR, albumin‐globulin ratio; ASA, American Society of Anesthesiologists; BMI, body mass index; HGPUC, high‐grade papillary urothelial carcinoma; IQR, interquartile range; LGPUC, low‐grade papillary urothelial carcinoma; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; NUC, non‐urothelial carcinoma; PLR, platelet‐lymphocyte ratio; PNI, prognostic nutritional index; PUNLMP, papillary urothelial neoplasm of low malignant potential; UC, urothelial carcinoma.

John Wiley & Sons, Ltd

We determined the cutoff values for the six factors for OS by calculating the maximum Youden index (fibrinogen‐3.295, NLR‐1.4388, PLR‐111, LMR‐3.4974, AGR‐1.5262, PNI‐50.95). Then patients were divided into low‐ and high‐risk groups according to the cutoff points. The AUC value was greater for fibrinogen than NLR and PLR for estimating OS (Figure [1](#cam42237-fig-0001){ref-type="fig"}).

![Receiver operating characteristic (ROC) curves for overall survival](CAM4-8-3447-g001){#cam42237-fig-0001}

Median follow‐up time after RARC was 20.6 months (1.2‐43.7 months). Fifty‐one patients (27.4%) died during follow‐up and 31 (16.7%) within 1 year from surgery. Table [2](#cam42237-tbl-0002){ref-type="table"} compares the preoperative risk factors for postoperative death within 1 year after RARC. One‐year mortality was significantly associated with age, clinical stage, fibrinogen, NLR, PLR, and PNI.

###### 

Comparison of preoperative risk factors for postoperative death within 1 year after RARC

  Variables                   Death within 1 year (31)   Death after 1 year (155)   *P* value
  --------------------------- -------------------------- -------------------------- -----------
  Age, years, median (IQR)    69 (51‐86)                 63 (32‐83)                 \<0.001
  Gender, n (%)                                                                     
  Male                        26 (83.9)                  131 (84.5)                 1.000
  Female                      5 (16.1)                   24 (15.5)                  
  BMI, kg/m^2^                23.31 (18‐32)              25.10 (16‐45)              0.070
  ASA score ≥3, n (%)         6 (19.4)                   20 (12.9)                  0.499
  No. of tumors, n (%)                                                              
  Solitary                    20 (64.5)                  78 (50.3)                  0.171
  Multiple                    11 (35.5)                  77 (49.7)                  
  Clinical stage, n (%)                                                             
  ≤T1                         2 (6.5)                    37 (23.9)                  0.001
  T2                          20 (64.5)                  105 (67.7)                 
  ≥T3                         9 (29.0)                   13(8.4)                    
  Pathological type, n (%)                                                          
  UC                          30 (96.8)                  146 (94.2)                 1.000
  NUC                         1 (3.2)                    9 (5.8)                    
  Pathological grade, n (%)                                                         
  PUNLMP                      0 (0.0)                    8 (5.9)                    0.338
  LGPUC                       8 (33.3)                   54 (39.7)                  
  HGPUC                       16 (66.7)                  74 (54.4)                  
  Hydronephrosis, n (%)                                                             
  Absent                      18 (58.1)                  119 (76.8)                 0.068
  Unilateral                  8 (25.8)                   26 (16.8)                  
  Bilateral                   5 (16.1)                   10 (6.5)                   
  Fibrinogen, n (%)                                                                 
  \<3.295                     11 (36.7)                  95 (63.8)                  0.008
  ≥3.295                      19 (63.3)                  54 (36.2)                  
  NLR, n (%)                                                                        
  \<1.4388                    0 (0.0)                    24 (15.5)                  0.016
  ≥1.4388                     31 (100.0)                 131 (84.5)                 
  PLR, n (%)                                                                        
  \<111                       5 (16.1)                   58 (37.4)                  0.023
  ≥111                        26 (83.9)                  97 (62.6)                  
  LMR, n (%)                                                                        
  \<3.4974                    2 (6.5)                    14 (9.0)                   1.000
  ≥3.4974                     29 (93.5)                  141 (91.0)                 
  AGR, n (%)                                                                        
  \<1.5262                    28 (90.3)                  134 (86.5)                 0.771
  ≥1.5262                     3 (9.7)                    21 (13.5)                  
  PNI, n (%)                                                                        
  \<50.95                     25 (80.6)                  87 (56.1)                  0.015
  ≥50.95                      6 (19.4)                   68 (43.9)                  

Abbreviations: AGR, albumin‐globulin ratio; ASA, American Society of Anesthesiologists; BMI, body mass index; HGPUC, high‐grade papillary urothelial carcinoma; IQR, interquartile range; LGPUC, low‐grade papillary urothelial carcinoma; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; NUC, non‐urothelial carcinoma; PLR, platelet‐lymphocyte ratio; PNI, prognostic nutritional index; PUNLMP, papillary urothelial neoplasm of low malignant potential; UC, urothelial carcinoma.
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In Cox univariate analysis, six prognostic variables were associated with higher risk of early death within 1 year after RARC: older age (*P* = 0.004), advanced clinical stage (*P* = 0.005), presence of hydronephrosis (*P* = 0.021), higher fibrinogen (*P* = 0.007), higher PLR (*P* = 0.031) and lower PNI (*P* = 0.016) (Table [3](#cam42237-tbl-0003){ref-type="table"}). On multivariate Cox stepwise analysis, older age (\>60 years: HR = 7.303, 95% CI 1.734‐30.764; *P* = 0.007) (Figure [2](#cam42237-fig-0002){ref-type="fig"}) and higher fibrinogen (≥3.295 g/L: HR = 2.396, 95% CI 1.138‐5.045; *P* = 0.007) (Figure [3](#cam42237-fig-0003){ref-type="fig"}) remained independently associated with 1‐year mortality after RARC (Table [4](#cam42237-tbl-0004){ref-type="table"}).

###### 

Preoperative prognostic factors for 1‐year mortality after RARC according to univariate COX regression

  Variables                              HR       95%CI            *P* value
  -------------------------------------- -------- ---------------- -----------
  Age (\>60 vs ≤60)                      8.37     2.00‐35.08       0.004
  Gender (male vs female)                0.959    0.368‐2.496      0.931
  BMI (≥22.6 vs \<22.6)                  0.542    0.267‐1.099      0.089
  ASA score (≥3 vs \<3)                  1.526    0.626‐3.720      0.353
  No. of tumors (multiple vs solitary)   0.599    0.287‐1.251      0.173
  Clinical stage (vs. ≤T1)                                         
  T2                                     3.264    0.763‐13.966     0.111
  ≥T3                                    9.217    1.990‐42.690     0.005
  Pathological type (NUC vs UC)          0.568    0.077‐4.163      0.578
  Pathological grade (HGPUC vs LGPUC)    1.372    0.587‐3.207      0.465
  Hydronephrosis (present vs absent)     1.714    1.086‐2.706      0.021
  Fibrinogen (high vs low)               2.787    1.326‐5.858      0.007
  NLR (high vs low)                      25.360   0.308‐2088.523   0.151
  PLR (high vs low)                      2.876    1.104‐7.490      0.031
  LMR (high vs low)                      1.363    0.325‐5.711      0.672
  AGR (high vs low)                      0.674    0.205‐2.218      0.517
  PNI (low vs high)                      3.002    1.231‐7.318      0.016

Abbreviations: AGR, albumin‐globulin ratio; ASA, American Society of Anesthesiologists; BMI, body mass index; HGPUC, high‐grade papillary urothelial carcinoma; IQR, interquartile range; LGPUC, low‐grade papillary urothelial carcinoma; LMR, lymphocyte‐monocyte ratio; NLR, neutrophil‐lymphocyte ratio; NUC, non‐urothelial carcinoma; PLR, platelet‐lymphocyte ratio; PNI, prognostic nutritional index; PUNLMP, papillary urothelial neoplasm of low malignant potential; UC, urothelial carcinoma.
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![Comparison of survival curves of bladder cancer patients at different ages](CAM4-8-3447-g002){#cam42237-fig-0002}

![Comparison of survival curves of bladder cancer patients with different preoperative plasma fibrinogen levels](CAM4-8-3447-g003){#cam42237-fig-0003}

###### 

Preoperative prognostic factors for 1‐year mortality after RARC by multivariate cox regression analysis

  Variables                    Adverse factor   HR      95% CI         *P* value
  ---------------------------- ---------------- ------- -------------- -----------
  Age (years)                  \>60             7.303   1.734‐30.764   0.007
  Clinical stage (vs ≤T1)      T2                                      0.669
                               ≥T3                                     0.077
  Hydronephrosis (vs absent)   present                                 0.217
  Fibrinogen (g/L)             ≥3.295           2.396   1.138‐5.045    0.021
  PLR (vs low)                 High                                    0.196
  PNI (vs high)                Low                                     0.150

Abbreviations: CI, confidence interval; HR, hazard ratio; PLR, platelet‐lymphocyte ratio; PNI, prognostic nutritional index.

John Wiley & Sons, Ltd

4. DISCUSSION {#cam42237-sec-0008}
=============

Our goal was to identify preoperative risk factors predicting 1‐year mortality after RARC. Such early death might be caused by underestimation of tumor stage, aggressive characteristic of bladder cancer, or perioperative complications.[11](#cam42237-bib-0011){ref-type="ref"} We found that older age and higher plasma fibrinogen levels were individual predictors in the multivariate models. This may guide the urologist in oncologic outcome prediction and in choosing eligible patients who might benefit from adjuvant systemic therapy.

Traditionally, prognostic factors for bladder cancer have been focusing on tumor stage and histological grade. Noteworthy, older patients have more years to compound comorbidities which may influence survival of bladder cancer patients. It is unclear whether patient age is an independent prognostic factor for patients undergoing RARC and there is still much discrepancy in previous studies. Some studies have shown that age is associated with poor survival[12](#cam42237-bib-0012){ref-type="ref"}, [13](#cam42237-bib-0013){ref-type="ref"}, [14](#cam42237-bib-0014){ref-type="ref"} while others have suggested that it is not a prognostic factor in multivariate analysis.[15](#cam42237-bib-0015){ref-type="ref"}, [16](#cam42237-bib-0016){ref-type="ref"}, [17](#cam42237-bib-0017){ref-type="ref"} Although experienced surgeons could safely carry out RARC in elderly patients,[17](#cam42237-bib-0017){ref-type="ref"}, [18](#cam42237-bib-0018){ref-type="ref"} the present findings suggested that elderly patients (＞60 years) have worse OS compared with younger patients (≤60 years) undergoing RARC.

Many patients with bladder cancer were found to have hydronephrosis due to ureteral orifice obstruction by tumor. Although pathologic stage is regarded as crucial prognostic characteristic after radical cystectomy, the prognostic role of hydronephrosis has been investigated with conflicting results.[19](#cam42237-bib-0019){ref-type="ref"}, [20](#cam42237-bib-0020){ref-type="ref"}, [21](#cam42237-bib-0021){ref-type="ref"}, [22](#cam42237-bib-0022){ref-type="ref"} To the best our knowledge, the relationship between the presence of preoperative hydronephrosis and prognosis after RARC has not yet been investigated. In our study, we found that preoperative hydronephrosis was significantly associated with 1‐year mortality after RARC according to univariate cox regression. This could assist in assessing the prognosis of patients and deciding therapeutic plans preoperatively.

Increasing studies shows that an interactive relationship exists between haemostatic factors and tumor biology.[23](#cam42237-bib-0023){ref-type="ref"}, [24](#cam42237-bib-0024){ref-type="ref"} Fibrinogen, one of the haemostatic factors, is a plasmaglyco protein whick plays a key role in clot formation and wound healing.[24](#cam42237-bib-0024){ref-type="ref"} Previous studies have demonstrated that elevated pre‐therapeutic plasma fibrinogen levels are associated with worse outcome in patients with ovarian or endometrial cancer.[25](#cam42237-bib-0025){ref-type="ref"}, [26](#cam42237-bib-0026){ref-type="ref"}

Tanaka et al demonstrated that preoperative plasma fibrinogen level was an independent prognostic variable for poor survival after radical nephroureterectomy in patients with upper tract urothelial carcinoma.[24](#cam42237-bib-0024){ref-type="ref"} Liu and colleagues observed that elevated preoperative plasma fibrinogen level was an independent predictor of advanced clinical stage in patients with bladder cancer.[27](#cam42237-bib-0027){ref-type="ref"} However, the prognostic value of plasma fibrinogen levels for bladder cancer patients receiving radical cystectomy has not yet been reported. We believe that preoperative plasma fibrinogen levels might become a useful biomarker in clinical practice.

However, some limitations of the present study warrant mention. First, the study was limited by the inherent drawbacks of its retrospective design. Second, this study was a single, tertiary‐care institution study. Finally, the number of patients is somewhat small to make a final conclusion on this matter. Thus, we are conducting a prospective randomized study to confirm the results in real clinical practice.

5. CONCLUSIONS {#cam42237-sec-0009}
==============

In summary, age and preoperative plasma fibrinogen level are independent predictors for 1‐year mortality after RARC. To the best of our knowledge, this is the first study to investigate the prognostic value of preoperative plasma fibrinogen levels in bladder cancer patients treated with RARC. We believe that preoperative plasma fibrinogen levels might become a useful biomarker for innovative systemic therapy aiming at improving prognosis in these patients.
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